Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02214888
Recruitment Status : Terminated
First Posted : August 13, 2014
Last Update Posted : August 13, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Study to determine the efficacy (including American College of Rheumatology (ACR) 20 response rate), safety, and pharmacokinetics of BIRB 796 BS as monotherapy in patients with moderate to severe rheumatoid arthritis who have failed at least one disease modifying antirheumatic drug (DMARD)

Condition or disease Intervention/treatment Phase
Arthritis, Rheumatoid Drug: BIRB 796 BS, low dose Drug: BIRB 796 BS, high dose Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 170 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A 12 Week Double-blind, Randomized, Placebo-controlled Trial to Investigate Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets at Doses of 50 and 70 mg Administered Twice a Day in Patients With Active Rheumatoid Arthritis Who Have Failed at Least One DMARD
Study Start Date : May 2003
Actual Primary Completion Date : January 2004

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BIRB 796 BS, low dose Drug: BIRB 796 BS, low dose
Drug: Placebo
Experimental: BIRB 796 BS, high dose Drug: BIRB 796 BS, high dose
Placebo Comparator: Placebo Drug: Placebo



Primary Outcome Measures :
  1. Number of responders according to the American College of Rheumatology (ACR) 20 criteria [ Time Frame: after 12 weeks of treatment ]

Secondary Outcome Measures :
  1. Absolute differences to baseline in tender joint count (TJC, 68 joint count) [ Time Frame: up to 12 weeks ]
  2. Absolute differences to baseline swollen joint count (SJC, 66 joint count) [ Time Frame: up to 12 weeks ]
  3. Absolute differences to baseline in patients assessment of pain on a visual analogue scale (VAS) [ Time Frame: up to 12 weeks ]
  4. Absolute differences to baseline in patients global assessment of disease activity (PADA) on a VAS [ Time Frame: up to 12 weeks ]
  5. Absolute differences to baseline in physicians global assessment of disease activity on a VAS [ Time Frame: up to 12 weeks ]
  6. Absolute differences to baseline in patient's assessment of physical function measured by a standardised Health Assessment Questionnaire (HAQ) [ Time Frame: up to 12 weeks ]
  7. Absolute differences to baseline in concentration of C-reactive protein (CRP) [ Time Frame: up to 12 weeks ]
  8. Absolute differences to baseline in erythrocyte sedimentation rate (ESR) [ Time Frame: up to 12 weeks ]
  9. Number of responders to ACR 50 [ Time Frame: after 12 weeks of treatment ]
  10. Number of responders to ACR 70 [ Time Frame: after 12 weeks of treatment ]
  11. Number of responders to European League against Rheumatism (EULAR) response criteria [ Time Frame: after 12 weeks of treatment ]
  12. Number of drop-outs due to lack of efficacy, according to final assessment of investigator [ Time Frame: after 12 weeks of treatment ]
  13. Number of patients with adverse Events (AE) [ Time Frame: up to 12 weeks after first drug administration ]
  14. Number of patients with clinically relevant changes in laboratory tests [ Time Frame: up to 12 weeks after first drug administration ]
  15. Number of patients with clinically relevant changes in electrocardiogram (ECG) [ Time Frame: up to 12 weeks after first drug administration ]
  16. Number of patients with clinically relevant changes in vital signs [ Time Frame: up to 12 weeks after first drug administration ]
  17. Number of withdrawals due to AEs [ Time Frame: up to 12 weeks after first drug administration ]
  18. Cmax,ss (Maximum measured concentration of the analyte in plasma at steady state) [ Time Frame: up to 24 hours after last drug administration ]
  19. AUC0-t,ss (area under the drug plasma concentration-time curve over a dosing interval (t) at steady state [ Time Frame: up to 24 hours after last drug administration ]
  20. Cpre (predose concentration of the analyte in Plasma) [ Time Frame: up to 24 hours after last drug administration ]
  21. Cmin,ss (Minimum measured concentration of the analyte in plasma at steady state) [ Time Frame: up to 24 hours after last drug administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female from 18 to 75 years of age
  • Diagnosis of rheumatoid arthritis (RA) established according to ACR criteria and date of diagnosis > 6 months
  • Patient belonging to functional class I, II, or III
  • Failure of at least one DMARD due to lack of efficacy or tolerability
  • 2 out of the 3 following RA activity criteria: If this criterion is not met at visit 1, the whole set of RA activity criteria can be repeated at visit 2 (Repeated screening)

    • documentation of ≥ 9 swollen joints in a 66 joint count
    • documentation of ≥ 9 tender joints in a 68 joint count
    • C-reactive protein (CRP) ≥ 1.5 mg/dl or erythrocyte sedimentation rate (ESR) ≥ 28 mm/hr (or equivalent of ≥ 24mm/hr according to Panchenkov method)
  • Written informed consent in accordance with Good Clinical Practice (GCP) and local legislation given prior to any study procedures, including washout of prohibited medications
  • Only for centres participating in the pharmacokinetic (PK) substudy: Written informed consent in accordance with GCP and local legislation for participation in the PK substudy. Refusal to participate in the PK substudy is not an exclusion criterion for participation in the trial

Exclusion Criteria:

  • Inflammatory rheumatic disease other than RA
  • Treatment failure to a tumor necrosis factor (TNF)-blocking agent. Treatment failure is defined as not achieving at least an ACR 20 response (e.g. in a clinical trial) or - in clinical practice - having the TNF-blocking agent discontinued due to ineffectiveness
  • History of vasculitis (characterised by e.g. nail bed hemorrhages or infarcts, vasculitic purpura, ulcers or gangrene, multisensory neuropathy, vasculitic retinopathy or scleritis of eyes). Isolated rheumatoid nodules of the skin are not a criterion for exclusion
  • Serologic evidence of active hepatitis B and/or C
  • Known HIV-infection
  • History of prior tuberculosis infection or suspicion of active infection at screening based on results of chest x-ray not older than 6 months
  • History of cardiovascular, renal, neurologic, psychiatric, liver, gastrointestinal, immunologic or endocrine dysfunction if they are clinically significant. A clinically significant disease is defined as one which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study
  • Recent history of heart failure (i.e. three years or less) or myocardial infarction (i.e. one year or less) or patients with any cardiac arrhythmia requiring drug therapy
  • History of malignant disease in the last 5 years or suspicion of active malignant disease except successfully treated squamous or basal cell carcinoma of the skin
  • Screening ECG results outside of the reference range of clinical relevance including, but not limited to QTcB > 480 msec, PR interval > 240 msec, QRS interval > 110 msec according to central ECG evaluation
  • Clinically significant abnormal baseline hematology, blood chemistry or urinalysis if the abnormality defines a disease listed as an exclusion criterion or any of the following specific laboratory abnormalities: If this criterion is not met at visit 1, the laboratory assessments can be selectively repeated at visit 2 (Repeated screening)

    • alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin greater than upper limit of normal (ULN)
    • alkaline phosphatase, creatinine or white blood cell count greater than 1.5 x ULN
  • History of drug or alcohol abuse within the past two years or active drug or alcohol abuse, present alcohol intake more than three drinks per day
  • Female of childbearing potential (not 6 months post- menopausal or surgically sterilized) not using an approved form of birth control (hormonal contraceptives, oral or injectable/implantable, intra-uterine device (IUD))
  • Inability to comply with the protocol
  • Previous enrolment in this trial or previous exposure to BIRB 796 BS in another trial
  • Hypersensitivity to trial drug

To be assessed at visit 3 (Baseline):

  • Pregnancy (to be excluded by serum and urine beta human chorion-gonadotropin (βHCG)-test in women of childbearing potential) or breast feeding
  • Active vasculitis
  • Active infection or serious infectious diseases resulting in hospitalisation or requiring systemic anti-infective therapy within the last 4 weeks
  • DMARD treatment within the last 4 weeks
  • Last dose given within the specified time period for one of the following compounds or drugs:

    • Infliximab (Remicade®): 3 months
    • Adalimumab (D2E7): 3 months
    • Leflunomide: 3 months. If cholestyramine has been given for 10 days : 4 weeks
    • Investigational agent: 5- fold of the respective plasma half life or 4 weeks, whichever is longer
  • Treatment with systemic corticosteroids in a dose higher than 10 mg/day prednisone equivalent
  • Change in treatment with nonsteroidal antiinflammatory drugs (NSAIDs) or systemic corticosteroids within the last 4 weeks
  • Synovectomy, joint surgery, radio-/chemo synoviorthesis, adrenocorticotropic hormone (ACTH) or any steroid injections (intraarticular, intravenous or intramuscular) within the last 4 weeks
  • Participation in another clinical trial within the last 4 weeks

Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02214888    
Other Study ID Numbers: 1175.18
First Posted: August 13, 2014    Key Record Dates
Last Update Posted: August 13, 2014
Last Verified: August 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases